Loading...
•
Sep 30, 2022
Balchem Q3 2022 Earnings Report
Balchem reported solid growth in sales and earnings, driven by growth across all segments and strategic acquisitions.
Key Takeaways
Balchem Corporation reported third quarter net sales of $244.3 million, a 23.4% increase compared to the prior year quarter. GAAP net earnings were $25.2 million, resulting in GAAP earnings per share of $0.78. Adjusted EPS was $1.00. The company's growth was supported by sales growth in all three segments: Human Nutrition & Health, Animal Nutrition & Health, and Specialty Products, as well as strategic initiatives such as the acquisition of Bergstrom.
Net sales increased by 23.4% to $244.3 million, with growth in all three segments.
Adjusted EBITDA increased by 11.2% to $53.8 million.
GAAP net earnings increased by 0.9% to $25.2 million, with GAAP EPS of $0.78.
Adjusted net earnings increased by 8.0% to $32.4 million, with adjusted EPS of $1.00.
Balchem
Balchem
Balchem Revenue by Segment
Revenue by Segment
Human Nutrition & Health Revenue
CapyFin.comAnimal Nutrition & Health Revenue
CapyFin.comSpecialty Products Revenue
CapyFin.com Forward Guidance
I am very pleased with how the Balchem team continues to manage through the current market conditions, and how we have shown resilience and the ability to deliver strong results, even in challenging times. We remain excited about our future and our ability to provide solutions for the health and nutritional needs of the world while acting as strong stewards of all of our stakeholders.
Revenue & Expenses
Visualization of income flow from segment revenue to net income